Companies

PFW Advisors LLC Invests in Amgen Inc.

Published January 14, 2025

PFW Advisors LLC has made a significant move by acquiring a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the fourth quarter, as indicated by its latest Form 13F filing submitted to the Securities and Exchange Commission. The institutional investor purchased 4,238 shares of Amgen's stock, with a total value of approximately $1,105,000.

Other Institutional Investors Update Their Holdings

A number of other institutional investors and hedge funds have also been active in adjusting their holdings of Amgen shares. For instance, Pathway Financial Advisers LLC dramatically increased its stake in Amgen by 33,125.4% during the third quarter. As a result, Pathway Financial Advisers now holds 4,460,181 shares valued at $1,437,115,000 after acquiring an additional 4,446,757 shares that quarter. Similarly, International Assets Investment Management LLC grew its stake in Amgen by 6,812.4% during the same period, bringing its total ownership to 2,523,387 shares worth about $8,130,610,000 after purchasing 2,486,882 additional shares.

Assenagon Asset Management S.A. increased its Amgen holdings by 561.5% in the third quarter, now owning 1,539,733 shares valued at $496,117,000 after buying 1,306,982 shares in the last quarter. Granite Bay Wealth Management LLC also raised its position in Amgen by 9,058.1% during the second quarter, acquiring 756,460 shares worth $223,897,000, having increased its totals by 748,200 shares. Lastly, Nordea Investment Management AB boosted its holdings in Amgen by 40.7% in the fourth quarter, now owning 2,338,665 shares valued at $609,526,000 after acquiring an additional 676,598 shares.

Currently, institutional investors hold 76.50% of Amgen's stock.

Analyst Price Targets for Amgen

Amgen's Stock Performance

On Monday, shares of Amgen rose by 3.0%, increasing by $7.96 to reach $270.19. Trading volume reached 3,364,979 shares, compared to the average volume of 3,085,018. Over the last 52 weeks, Amgen's stock has traded between a low of $253.30 and a high of $346.85, and currently has a market capitalization of $145.24 billion. Other financial metrics for Amgen include a P/E ratio of 34.60, a P/E/G ratio of 2.91, and a beta of 0.56. The company’s debt-to-equity ratio is 7.55, current ratio is at 1.32, and quick ratio is 0.96. As of now, Amgen's fifty-day moving average is $279.10, while the two-hundred-day moving average stands at $308.66.

Amgen's Recent Earnings and Dividend Announcement

In its recent earnings report on October 30th, Amgen announced earnings of $5.58 per share, surpassing the consensus estimate of $5.11 by $0.47. The company achieved a net margin of 13.00% and a return on equity of 168.35%, alongside revenue of $8.50 billion which met analysts' expectations. When compared to the same quarter last year, Amgen's revenue displayed a 23.2% increase. Analysts forecast Amgen to post an EPS of 19.53 for the current year.

Furthermore, Amgen has declared a quarterly dividend, which will be distributed on March 7th. Shareholders on record as of February 14th will receive a dividend of $2.38 per share, reflecting an increase from the previous dividend of $2.25. This change signifies an annualized dividend of $9.52, yielding a dividend yield of 3.52%. Notably, Amgen's dividend payout ratio currently stands at 121.90%.

Overview of Amgen Inc.

Amgen Inc. is engaged in the research, development, manufacture, and distribution of human therapeutics on a global scale. Some of its principal products include Enbrel for conditions like plaque psoriasis and rheumatoid arthritis, Otezla for treating plaque psoriasis and Behçet's disease, and Prolia for osteoporosis in postmenopausal women. Amgen also offers drugs for other conditions, such as Nplate for immune thrombocytopenia, XGEVA for preventing skeletal-related events, and Repatha to reduce risks related to major cardiovascular illnesses.

For those interested in Amgen's stock and other hedge fund activities, checking the latest 13F filings and insider trades is advisable.

PFW, Advisors, Amgen